首页> 外文期刊>Nuclearmedicine >A family with pheochromocytoma-paraganglioma inherited tumour syndrome Serial F-18-DOPA PET/CT investigations
【24h】

A family with pheochromocytoma-paraganglioma inherited tumour syndrome Serial F-18-DOPA PET/CT investigations

机译:嗜铬细胞瘤旁神经节瘤家族遗传性肿瘤综合征系列F-18-DOPA PET / CT检查

获取原文
获取原文并翻译 | 示例
           

摘要

Aim: Hereditary pheochromocytoma-paraganglioma syndromes are characterized by multiple pheochromocytomas (PCC) and paragangliomas (PGLs), inherited in an autosomal dominant manner. Early detection and removal of tumours may prevent or minimize complications related to mass effects and malignant transformation. Having confirmed the diagnosis, it is important to localize the tumours and reveal their extent preoperatively. This study aimed to introduce F-18-DOPA PET/CT as a highly sensitive non-invasive diagnostic tool for early detection of mass lesions in patients with pheochromocytoma-paraganglioma inherited tumour syndrome and to report about its impact on patient management. Patients, methods: We are currently supervising one of the largest documented families in Germany with genetically determined SDHD gene mutation. We performed F-18-DOPA PET/CT in order to detect tumours in asymptomatic gene carriers and enable subsequent surgical therapy. Results: In seven patients undergoing 12 F-18-DOPA PET/CT scans 17 lesions have been detected. Three of these lesions, located in the head and neck region, have had no morphologic correlate in CT and one had also no morphologic correlate in MRI. Of the six histologically analyzed lesions five have been tumors (PGL or PCC) and one has been a nodular hyperplasia. This means the F-18-DOPA PET/CT scan in our study group had a sensitivity of 83%. F-18-DOPA PET/CT investigations lead to change in the management in 5/7 studied patients (70%). Conclusion: The benefits of PET/CT in detection of pheochromocytoma and paraganglioma are well documented, but we are the first to use this technique for screening of a rare hereditary disease (estimated prevalence 0.3/100000).
机译:目的:遗传性嗜铬细胞瘤-副神经节瘤综合征的特征是多发性嗜铬细胞瘤(PCC)和副神经节瘤(PGL),以常染色体显性遗传。早期发现和清除肿瘤可以预防或最小化与肿块效应和恶性转化有关的并发症。确认诊断后,重要的是要定位肿瘤并在术前揭示其范围。这项研究旨在介绍F-18-DOPA PET / CT作为一种高度敏感的非侵入性诊断工具,用于早期发现嗜铬细胞瘤-副神经节瘤遗传性肿瘤综合征患者的肿块,并报告其对患者管理的影响。患者,方法:我们目前正在监督德国有基因记录的SDHD基因突变的最大家庭之一。为了检测无症状基因携带者中的肿瘤并进行后续的手术治疗,我们进行了F-18-DOPA PET / CT。结果:在接受12次F-18-DOPA PET / CT扫描的7例患者中,发现了17个病变。这些病变中的三个位于头部和颈部区域,在CT中没有形态相关,在MRI中也没有形态相关。经组织学分析的六个病变中,五个是肿瘤(PGL或PCC),一个是结节性增生。这意味着我们研究组中的F-18-DOPA PET / CT扫描灵敏度为83%。 F-18-DOPA PET / CT研究导致5/7研究患者(70%)的治疗改变。结论:PET / CT在检测嗜铬细胞瘤和副神经节瘤方面的优势已得到充分证明,但我们是第一个使用此技术筛查罕见遗传性疾病(估计患病率为0.3 / 100000)的人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号